Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jan 09, 2022 12:57pm
144 Views
Post# 34297703

RE:RE:Covid implications for meetings with shareholders

RE:RE:Covid implications for meetings with shareholdersMy daughter just got back from visiting her in-laws in Cancouver and she had to get tests in both directions. On the US side, it may be the airline required it rather than the government, but it was the same for her both ways. And it was a huge hassle and massively expensive for her to get it done on the US side due to a lack of tests ($250 each for her and her husband to get the test at the airport where they had to show up at 6AM to get the tests after being turned away the previous evening after they waited in very long lines for a long time because the testing operation shut down).

palinc2000 wrote:

Very easy for Canadians to enter the US All you need is proof that you are fully vaccinated! .... Entering Canada is a bit more complicated since in addition to the vax proof you need a negative PCR test before entering....
I must say that I see some  negative implications in THTX calling for a Meeting with large shareholders .....Seems to me like a mitigating measure to hold on to large shareholders .Normally good news is followed by a herd of new shareholders and there is no need to hold closed door private meetings with current shareholders

 



 

o

SPCEO1 wrote: While there appears to be a fair amount of unnecessary angst among some here about these meetings with large shareholders in late January, there is a very good chance they never actually happen due to covid. It seems like most think the current wave may be peaking around then and Quebec has already pretty much locked down. It may be that TH executives could not easily get out of Montreal or, more likely, would not be able to easily get back in if they traveled to the US for these meetings. So, these meetings may not even happen. 

But the hint we got from TH even scheduling them in the first place remains in place and still gives us a good idea about the timing of any news they may be sharing shortly. 

The biggest hint we have on the most important subject for TH right now is the fact that the trial is apparently still ongoing. So, very large doses of TH-1902 are still being given to patients and the odds that those patients with sortilin overexpressing cancers are seeing some positive impact on their tumors grows each day. The reality of the situation is likely a lot messier than that behind the scenes of the trial but, nevertheless, the longer the trial goes on the better our chances.  

On the whole silence, addition of Pfizer's recently retired CMO, removal of the corporate presentation, scheduling of meetings with large shareholders, etc. thing, it smells to me like a meaningful deal of some sort has been agreed upon that is now just waiting for a board's approval before being formally announced. I have no idea what sort of deal that might be, and it seems to me to be way too early for a really big partnership deal or an acquiisition of TH, but the circumstances still have a bit of that feel to it. I can see a Chinese partnership deal being struck at this early stage as the Chinese seem to be pretty agressive at the moment, or perhpaps a partnership with a Western drug company for a single aspect of the Sort1+ approach just to validate what TH is up to in the eyes of investors, but it seems too early for something bigger than that to be announced. And it may just be an announcement that there has been preliminary efficacy seen in phase 1a. But it still smells like something bigger might be happening. That may more reflect my overactive imagination than anything else. It borders on one of my wild speculations but there are enough hints out there now to make it not quite reach the threshhold of a wild speculation.

We will know soon enough.  

 

 



<< Previous
Bullboard Posts
Next >>